Clinical Management of Pediatric Acute-Onset Neuropsychiatric Syndrome: Part II-Use of Immunomodulatory Therapies.

@article{Frankovich2017ClinicalMO,
  title={Clinical Management of Pediatric Acute-Onset Neuropsychiatric Syndrome: Part II-Use of Immunomodulatory Therapies.},
  author={Jennifer Frankovich and Susan E. Swedo and Tanya K. Murphy and Russell C. Dale and Dritan Agalliu and Kyle Allen Williams and Michael Daines and Mady Hornig and Harry T. Chugani and Terry D. Sanger and Eyal Muscal and Mark S. Pasternack and Michael S. Cooperstock and Hayley A. Gans and Yujuan Zhang and Madeleine W. Cunningham and Gail A. Bernstein and Reuven Bromberg and Theresa Willett and Kayla D Brown and Bahare Farhadian and Kiki D Chang and Daniel A. Geller and Joseph D Hernandez and Janell Sherr and Richard Shaw and Elizabeth Latimer and James Frederick Leckman and Margo Thienemann},
  journal={Journal of child and adolescent psychopharmacology},
  year={2017},
  volume={27 7},
  pages={
          574-593
        }
}
Introduction: Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) is a clinically heterogeneous disorder with a number of different etiologies and disease mechanisms. Inflammatory and postinfectious autoimmune presentations of PANS occur frequently, with some clinical series documenting immune abnormalities in 75%-80% of patients. Thus, comprehensive treatment protocols must include immunological interventions, but their use should be reserved only for PANS cases in which the symptoms… 

Tables from this paper

Clinical Management of Pediatric Acute-Onset Neuropsychiatric Syndrome: Part III-Treatment and Prevention of Infections.

A working guideline for the management of infection issues in PANS and PANDAS, based on literature and expert opinion, is provided.

Overview of Treatment of Pediatric Acute-Onset Neuropsychiatric Syndrome.

Treatment of PANS depends on three complementary modes of intervention, ranging from psychological trauma or underlying neurological, endocrine, and metabolic disorders to postinfectious autoimmune and neuroinflammatory disorders, including pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections.

Course of Neuropsychiatric Symptoms After Introduction and Removal of Nonsteroidal Anti-Inflammatory Drugs: A Pediatric Observational Study.

Improvement in neuropsychiatric symptoms was evident in roughly one-third of NSAID treatment trials, and a randomized clinical trial will be necessary to confirm whether NSAIDs are successful in reducing neuroPsychiatric symptoms in youth with PANS.

Pediatric Acute-Onset Neuropsychiatric Syndrome Response to Oral Corticosteroid Bursts: An Observational Study of Patients in an Academic Community-Based PANS Clinic.

Coricosteroids may be a helpful treatment intervention in patients with new-onset and relapsing/remitting PANS and PANDAS, hastening symptom improvement or resolution when corticosteroids are given earlier in a disease flare, symptoms improve more quickly and patients achieve clinical remission sooner.

Effect of Early and Prophylactic Nonsteroidal Anti-Inflammatory Drugs on Flare Duration in Pediatric Acute-Onset Neuropsychiatric Syndrome: An Observational Study of Patients Followed by an Academic Community-Based Pediatric Acute-Onset Neuropsychiatric Syndrome Clinic.

NSAIDs given prophylactically or within 30 days of flare onset may shorten neuropsychiatric symptom duration in patients with new-onset and relapsing/remitting PANS and PANDAS.

Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infection (PANDAS): Clinical Manifestations, IVIG Treatment Outcomes, Results from a Cohort of Italian Patients

In this study, IVIG has been shown to be effective in most of the cases and no complications have been reported during the treatment.

PANS and PANDAS: Case series of patients in a Danish pediatric clinical cohort.

A positive effect of acute and prophylactic antibiotic-, psychiatric- and immunomodulating treatment, according to parental reports is shown.

Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (Review)

A thorough review of the literature was carried out using the PubMed database and SCOPUS, searching for immunological, clinical and microbiological aspects, as well as the treatment of the PANDAS syndrome, to establish the best method of therapy.

Treatment barriers in PANS/PANDAS: Observations from eleven health care provider families.

Improvement in PANDAS/PANS education of clinicians who may encounter children with this disorder is 1 key step toward addressing the identified barriers.

Immunological causes of obsessive-compulsive disorder: is it time for the concept of an “autoimmune OCD” subtype?

The novel concept of “autoimmune OCD” is proposed for a small subgroup of OCD patients, and clinical signs based on the PANDAS/PANS criteria and from recent experience with autoimmune encephalitis and autoimmune psychosis are suggested.

References

SHOWING 1-10 OF 102 REFERENCES

Clinical Management of Pediatric Acute-Onset Neuropsychiatric Syndrome: Part III-Treatment and Prevention of Infections.

A working guideline for the management of infection issues in PANS and PANDAS, based on literature and expert opinion, is provided.

Course of Neuropsychiatric Symptoms After Introduction and Removal of Nonsteroidal Anti-Inflammatory Drugs: A Pediatric Observational Study.

Improvement in neuropsychiatric symptoms was evident in roughly one-third of NSAID treatment trials, and a randomized clinical trial will be necessary to confirm whether NSAIDs are successful in reducing neuroPsychiatric symptoms in youth with PANS.

Pediatric Acute-Onset Neuropsychiatric Syndrome Response to Oral Corticosteroid Bursts: An Observational Study of Patients in an Academic Community-Based PANS Clinic.

Coricosteroids may be a helpful treatment intervention in patients with new-onset and relapsing/remitting PANS and PANDAS, hastening symptom improvement or resolution when corticosteroids are given earlier in a disease flare, symptoms improve more quickly and patients achieve clinical remission sooner.

From Research Subgroup to Clinical Syndrome: Modifying the PANDAS Criteria to Describe PANS (Pediatric Acute-onset Neuropsychiatric

Modifying the PANDAS criteria to eliminate etiologic factors and to clarify the initial clinical presentation produced three potential diagnostic criteria for PANS, which are discussed in detail.

Clinical evaluation of youth with pediatric acute-onset neuropsychiatric syndrome (PANS): recommendations from the 2013 PANS Consensus Conference.

A consensus statement is presented proposing recommendations for the diagnostic evaluation of youth presenting with PANS and the most urgently needed studies in this field are set forth.

Five youth with pediatric acute-onset neuropsychiatric syndrome of differing etiologies.

Pediatric acute-onset neuropsychiatric syndrome may present in differing ways, with psychiatric and physical symptoms overlapping with inflammatory or infectious diseases, pain syndromes, and other psychiatric diagnoses.

Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives

The most common pharmacological treatments used in NPSLE are described, based on both a literature search and expert opinion, which indicate that anticoagulation and antiplatelet agents are the mainstay of therapy when symptoms are thought to reflect a thrombotic underlying process.

Autoimmune Encephalopathies

Autoimmune encephalopathies are an important cause of rapidly progressive cognitive and behavioral decline that probably remain under recognized and Electroencephalography, brain MRI, cerebrospinal fluid examination and serological tests are useful diagnostic tools.

Multidisciplinary clinic dedicated to treating youth with pediatric acute-onset neuropsychiatric syndrome: presenting characteristics of the first 47 consecutive patients.

Those with and without acute onset of symptoms had similar symptom presentation, rates of inflammatory conditions, somatic symptoms, and violent thoughts and behaviors.

Autoimmune encephalitis in children: clinical phenomenology, therapeutics, and emerging challenges

Auto-antibodies that bind to conformational extracellular epitopes of neuronal receptors or synaptic proteins have provided clinicians with essential biomarkers in acute neurology and future priorities include the need for paediatric-specific consensus definitions for seronegative suspected autoimmune encephalitis.
...